Trial Profile

A Prospective, Multicenter, Observational Study of LUMRYZ Used in Clinical Practice for the Treatment of Narcolepsy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sodium oxybate (Primary)
Indications Narcolepsy
Focus Therapeutic Use
Acronyms REFRESH
Sponsors Avadel Pharmaceuticals

Most Recent Events

04 Jun 2026 According to an Alkermes plc media release, data from the trial will be presented at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore.
13 Feb 2026 Status changed from active, no longer recruiting to completed.
30 Sep 2025 Planned End Date changed from 1 Jul 2025 to 1 Oct 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com